Article

Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.

Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and  history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.

Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.

Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.

Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and  history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.

Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.

Key clinical point: Increased risk for venous thromboembolism (VTE) in patients with psoriatic arthritis (PsA) seemed to be associated with underlying comorbidities and not independently associated with PsA.

Major finding: During follow-up, 1.2% vs. 0.8% patients in the PsA vs. control group were diagnosed with VTE, but this association was not statistically significant after adjusting for demographic factors and comorbidities (adjusted hazard ratio [aHR] 1.27; P = .16) with only older age (aHR 1.08; P < .0001) and  history of VTE (aHR 31.63; P < .0001) remaining associated with an increased risk for VTE after multivariate adjustment.

Study details: This retrospective cohort study included 5,275 patients with newly diagnosed PsA who were matched with 21,011 control individuals without PsA.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gazitt T et al. Arthritis Res Ther. 2022;24:16 (Jan 7). Doi: 10.1186/s13075-021-02703-8.

Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.

Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).

Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.

Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.

Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.

Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.

Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).

Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.

Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.

Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.

Key clinical point: Patients with juvenile psoriatic arthritis (JPsA) were more likely to develop uveitis if they were diagnosed with PsA at a younger age or were antinuclear antibody (ANA) positive, with higher disease activity being the only factor significantly associated with the presence of uveitis.

Major finding: Patients with JPsA with vs. without uveitis were younger at JPsA onset (5.3 years vs. 9.3 years) and were more frequently positive for ANA (60.3% vs. 37%; both P < .001). The mean clinical Juvenile Arthritis Disease Activity Score 10 was the only factor significantly associated with the development of uveitis in patients with JPsA (hazard ratio 1.16; P = .025).

Study details: This was an analysis of cross-sectional data from 1,862 patients with JPsA from the National Pediatric Rheumatological Database. Of the patients in the study, 122 developed uveitis.

Disclosures: This study was funded by the Federal Ministry for Research and Education, Deutsche Kinderrheuma-Stiftung, and others. Some of the authors declared receiving honoraria and research grants from several sources.

Source: Walscheid K et al. J Rheumatol. 2022 (Jan 15). Doi: 10.3899/jrheum.210755.

Key clinical point: Patients with psoriasis and concomitant psoriatic arthritis (PsA) were at greater risk of developing endometriosis.

Major finding: A history of psoriasis with concomitant PsA was associated with an increased risk for subsequent endometriosis diagnosis (hazard ratio [HR] 2.01; 95% CI 1.23-3.30), which persisted even after adjusting for comorbidities such as hypertension, hypercholesterolemia, and cardiovascular disease (HR 1.94; 95% CI 1.18-3.18).

Study details: Findings are from an analysis of 4,112 patients with laparoscopically confirmed endometriosis and 767 patients with psoriasis, of which 140 had concomitant PsA from the Nurses’ Health Study II.

Disclosures: This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. The authors reported no conflicts of interest.

Source: Harris HR et al. Am J Epidemiol. 2022 (Jan 13). Doi: 10.1093/aje/kwac009.

Key clinical point: Patients with psoriasis and concomitant psoriatic arthritis (PsA) were at greater risk of developing endometriosis.

Major finding: A history of psoriasis with concomitant PsA was associated with an increased risk for subsequent endometriosis diagnosis (hazard ratio [HR] 2.01; 95% CI 1.23-3.30), which persisted even after adjusting for comorbidities such as hypertension, hypercholesterolemia, and cardiovascular disease (HR 1.94; 95% CI 1.18-3.18).

Study details: Findings are from an analysis of 4,112 patients with laparoscopically confirmed endometriosis and 767 patients with psoriasis, of which 140 had concomitant PsA from the Nurses’ Health Study II.

Disclosures: This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. The authors reported no conflicts of interest.

Source: Harris HR et al. Am J Epidemiol. 2022 (Jan 13). Doi: 10.1093/aje/kwac009.

Key clinical point: Patients with psoriasis and concomitant psoriatic arthritis (PsA) were at greater risk of developing endometriosis.

Major finding: A history of psoriasis with concomitant PsA was associated with an increased risk for subsequent endometriosis diagnosis (hazard ratio [HR] 2.01; 95% CI 1.23-3.30), which persisted even after adjusting for comorbidities such as hypertension, hypercholesterolemia, and cardiovascular disease (HR 1.94; 95% CI 1.18-3.18).

Study details: Findings are from an analysis of 4,112 patients with laparoscopically confirmed endometriosis and 767 patients with psoriasis, of which 140 had concomitant PsA from the Nurses’ Health Study II.

Disclosures: This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health. The authors reported no conflicts of interest.

Source: Harris HR et al. Am J Epidemiol. 2022 (Jan 13). Doi: 10.1093/aje/kwac009.

Key clinical point: Secukinumab showed early and clinically meaningful improvements in patient-reported outcomes (PRO) in adults with psoriatic arthritis (PsA).

Major finding: At week 16, patients in all secukinumab treatment groups vs. placebo showed significant improvement in all PRO (P ≤ .0001) except for the 36-item Short-Form Health Survey mental component summary. Patients receiving 300 mg secukinumab showed significant and clinically meaningful improvements as early as week 1 (P < .05).

Study details: Findings are from the phase 3 FUTURE 5 trial including 996 adults with active PsA who were randomly assigned to 300 mg secukinumab, 150 mg secukinumab  (with/without loading dose), or placebo.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants or consulting and speaker’s bureau fees from various sources including Novartis. Four authors declared being past/current employees or shareholders of Novartis.

Source: Strand V et al. Lancet Rheumatol. 2022 (Feb 1). Doi: 10.1016/S2665-9913(21)00354-4.

Key clinical point: Secukinumab showed early and clinically meaningful improvements in patient-reported outcomes (PRO) in adults with psoriatic arthritis (PsA).

Major finding: At week 16, patients in all secukinumab treatment groups vs. placebo showed significant improvement in all PRO (P ≤ .0001) except for the 36-item Short-Form Health Survey mental component summary. Patients receiving 300 mg secukinumab showed significant and clinically meaningful improvements as early as week 1 (P < .05).

Study details: Findings are from the phase 3 FUTURE 5 trial including 996 adults with active PsA who were randomly assigned to 300 mg secukinumab, 150 mg secukinumab  (with/without loading dose), or placebo.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants or consulting and speaker’s bureau fees from various sources including Novartis. Four authors declared being past/current employees or shareholders of Novartis.

Source: Strand V et al. Lancet Rheumatol. 2022 (Feb 1). Doi: 10.1016/S2665-9913(21)00354-4.

Key clinical point: Secukinumab showed early and clinically meaningful improvements in patient-reported outcomes (PRO) in adults with psoriatic arthritis (PsA).

Major finding: At week 16, patients in all secukinumab treatment groups vs. placebo showed significant improvement in all PRO (P ≤ .0001) except for the 36-item Short-Form Health Survey mental component summary. Patients receiving 300 mg secukinumab showed significant and clinically meaningful improvements as early as week 1 (P < .05).

Study details: Findings are from the phase 3 FUTURE 5 trial including 996 adults with active PsA who were randomly assigned to 300 mg secukinumab, 150 mg secukinumab  (with/without loading dose), or placebo.

Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants or consulting and speaker’s bureau fees from various sources including Novartis. Four authors declared being past/current employees or shareholders of Novartis.

Source: Strand V et al. Lancet Rheumatol. 2022 (Feb 1). Doi: 10.1016/S2665-9913(21)00354-4.

Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.

Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.

Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.

Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.

Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi:  10.1016/j.jaip.2021.11.034.

Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.

Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.

Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.

Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.

Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi:  10.1016/j.jaip.2021.11.034.

Key clinical point: The risk for all-cause and atopic dermatitis (AD)-related hospitalization was significantly lower in adult patients with moderate-to-severe AD who received dupilumab vs. placebo.

Major finding: Risk for all-cause hospitalizations was lower by 62% (risk ratio [RR] 0.38; P < .001) and AD-related hospitalizations by 79% (RR 0.21; P < .001) in patients who received dupilumab vs. placebo.

Study details: Findings are from a post hoc analysis of pooled data from 7 phase 2/3 trials including 2,932 patients with moderate-to-severe AD who were randomly assigned to 300 mg dupilumab (every 2 weeks or weekly) with or without topical corticosteroids or placebo for 12, 16, or 52 weeks.

Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants or receiving grants and honoraria from several sources. Six authors declared being employees or shareholders of Sanofi or Regeneron or Sanofi Genzyme.

Source: Silverberg JI et al. J Allergy Clin Immunol Pract. 2022 (Jan 12). Doi:  10.1016/j.jaip.2021.11.034.

Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.

Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.

Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.

Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309

Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.

Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.

Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.

Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309

Key clinical point: Under real-world settings, dupilumab was an effective and safe therapeutic option for adolescents and adults with moderate-to-severe atopic dermatitis (AD).

Major finding: At least 75% improvement in the Eczema Area and Severity Index was achieved by 53.3% and 79.4% of patients at weeks 12 and 48, respectively. Overall, mild adverse events were reported by 32% of patients, with the most frequent being conjunctivitis, persistent facial erythema, and arthritis/arthralgia.

Study details: Findings are from a nationwide, retrospective 48-week study including 169 patients aged 12 years or older with moderate-to-severe AD who received dupilumab.

Disclosures: This study did not report any source of funding. Some authors declared serving as a speakers and principal investigators or receiving consulting fees, research grants, and honoraria from several sources.

Source: Torres T et al. J Dermatolog Treat. 2022 (Jan 31). Doi: 10.1080/09546634.2022.2035309

Key clinical point: The risk for overall infection was not higher in children and adolescents with moderate-to-severe or severe atopic dermatitis (AD) treated with dupilumab vs. placebo; however, the risk for skin infections was significantly lower with dupilumab.

Major finding: Dupilumab did not increase the risk for overall infections (risk ratio [RR] 0.76; P = .051) and was associated with a reduced risk for total skin infections (RR 0.45; P = .003) compared with placebo.

Study details: This was a pooled analysis of 2 phase 3 trials including 612 adolescents or children with moderate-to-severe/severe AD who received dupilumab either as monotherapy (LIBERTY AD ADOL) or with concomitant topical corticosteroids (LIBERTY AD PEDS).

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as investigators, speakers, consultants, and scientific advisors or clinical study investigators, and advisory board members or receiving honoraria and grants from several sources. Six authors declared being employees or shareholders of Sanofi and Regeneron Pharmaceuticals.

Source: Paller AS et al. Pediatr Dermatol. 2022 (Jan 26). Doi: 10.1111/pde.14909

Key clinical point: The risk for overall infection was not higher in children and adolescents with moderate-to-severe or severe atopic dermatitis (AD) treated with dupilumab vs. placebo; however, the risk for skin infections was significantly lower with dupilumab.

Major finding: Dupilumab did not increase the risk for overall infections (risk ratio [RR] 0.76; P = .051) and was associated with a reduced risk for total skin infections (RR 0.45; P = .003) compared with placebo.

Study details: This was a pooled analysis of 2 phase 3 trials including 612 adolescents or children with moderate-to-severe/severe AD who received dupilumab either as monotherapy (LIBERTY AD ADOL) or with concomitant topical corticosteroids (LIBERTY AD PEDS).

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as investigators, speakers, consultants, and scientific advisors or clinical study investigators, and advisory board members or receiving honoraria and grants from several sources. Six authors declared being employees or shareholders of Sanofi and Regeneron Pharmaceuticals.

Source: Paller AS et al. Pediatr Dermatol. 2022 (Jan 26). Doi: 10.1111/pde.14909

Key clinical point: The risk for overall infection was not higher in children and adolescents with moderate-to-severe or severe atopic dermatitis (AD) treated with dupilumab vs. placebo; however, the risk for skin infections was significantly lower with dupilumab.

Major finding: Dupilumab did not increase the risk for overall infections (risk ratio [RR] 0.76; P = .051) and was associated with a reduced risk for total skin infections (RR 0.45; P = .003) compared with placebo.

Study details: This was a pooled analysis of 2 phase 3 trials including 612 adolescents or children with moderate-to-severe/severe AD who received dupilumab either as monotherapy (LIBERTY AD ADOL) or with concomitant topical corticosteroids (LIBERTY AD PEDS).

Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as investigators, speakers, consultants, and scientific advisors or clinical study investigators, and advisory board members or receiving honoraria and grants from several sources. Six authors declared being employees or shareholders of Sanofi and Regeneron Pharmaceuticals.

Source: Paller AS et al. Pediatr Dermatol. 2022 (Jan 26). Doi: 10.1111/pde.14909

Key clinical point: Salivary cortisol levels were neither associated with the severity of atopic dermatitis (AD) nor could measure the stress associated with it.

Major finding: Salivary cortisol levels increased in both symptomatic and asymptomatic patients, but the levels were significantly lower in symptomatic vs. asymptomatic patients (P = .011) and those with severe vs. moderate and mild disease (P = .042). However, the severity of perceived stress could neither be measured by cortisol levels nor by disease severity.

Study details: Findings are from a prospective study including symptomatic (n = 42) and asymptomatic (n =               42) patients with AD.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Meštrović-Štefekov  J et al. Dermatitis. 2022 (Jan 25). Doi: 10.1097/DER.0000000000000834.

Key clinical point: Salivary cortisol levels were neither associated with the severity of atopic dermatitis (AD) nor could measure the stress associated with it.

Major finding: Salivary cortisol levels increased in both symptomatic and asymptomatic patients, but the levels were significantly lower in symptomatic vs. asymptomatic patients (P = .011) and those with severe vs. moderate and mild disease (P = .042). However, the severity of perceived stress could neither be measured by cortisol levels nor by disease severity.

Study details: Findings are from a prospective study including symptomatic (n = 42) and asymptomatic (n =               42) patients with AD.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Meštrović-Štefekov  J et al. Dermatitis. 2022 (Jan 25). Doi: 10.1097/DER.0000000000000834.

Key clinical point: Salivary cortisol levels were neither associated with the severity of atopic dermatitis (AD) nor could measure the stress associated with it.

Major finding: Salivary cortisol levels increased in both symptomatic and asymptomatic patients, but the levels were significantly lower in symptomatic vs. asymptomatic patients (P = .011) and those with severe vs. moderate and mild disease (P = .042). However, the severity of perceived stress could neither be measured by cortisol levels nor by disease severity.

Study details: Findings are from a prospective study including symptomatic (n = 42) and asymptomatic (n =               42) patients with AD.

Disclosures: The study did not report any source of funding. The authors declared no conflicts of interest.

Source: Meštrović-Štefekov  J et al. Dermatitis. 2022 (Jan 25). Doi: 10.1097/DER.0000000000000834.

Key clinical point: Moderate-to-severe lower respiratory tract infection (LRTI) before 18 months of age is a significant risk factor for developing atopic dermatitis (AD) in later childhood.

Major finding: The group of infants with moderate-severe vs. no or mild LRTI had significantly higher rates of AD at age 3 years (P = .001) and 5 years (P = .006) with moderate-to-severe vs. no LRTI in the first 18 months of life being significantly associated with increased odds of AD in later childhood (odds ratio [OR] 2.19; P < .001) independent of both-parent history of asthma and both-parent genetic predisposition.

Study details: Findings are from the Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study, comprising a longitudinal birth cohort of 3,272 parents and infants recruited during pregnancy and followed from birth onwards.

Disclosures: This study was funded by the Canadian Institutes of Health Research and Allergy, Genes, and Environment Network of Centers of Excellence. The authors declared no conflicts of interest.

Source: Medeleanu M et al. J Allergy Clin Immunol. 2022 (Jan 16). Doi: 10.1016/j.jacig.2021.12.005

Key clinical point: Moderate-to-severe lower respiratory tract infection (LRTI) before 18 months of age is a significant risk factor for developing atopic dermatitis (AD) in later childhood.

Major finding: The group of infants with moderate-severe vs. no or mild LRTI had significantly higher rates of AD at age 3 years (P = .001) and 5 years (P = .006) with moderate-to-severe vs. no LRTI in the first 18 months of life being significantly associated with increased odds of AD in later childhood (odds ratio [OR] 2.19; P < .001) independent of both-parent history of asthma and both-parent genetic predisposition.

Study details: Findings are from the Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study, comprising a longitudinal birth cohort of 3,272 parents and infants recruited during pregnancy and followed from birth onwards.

Disclosures: This study was funded by the Canadian Institutes of Health Research and Allergy, Genes, and Environment Network of Centers of Excellence. The authors declared no conflicts of interest.

Source: Medeleanu M et al. J Allergy Clin Immunol. 2022 (Jan 16). Doi: 10.1016/j.jacig.2021.12.005

Key clinical point: Moderate-to-severe lower respiratory tract infection (LRTI) before 18 months of age is a significant risk factor for developing atopic dermatitis (AD) in later childhood.

Major finding: The group of infants with moderate-severe vs. no or mild LRTI had significantly higher rates of AD at age 3 years (P = .001) and 5 years (P = .006) with moderate-to-severe vs. no LRTI in the first 18 months of life being significantly associated with increased odds of AD in later childhood (odds ratio [OR] 2.19; P < .001) independent of both-parent history of asthma and both-parent genetic predisposition.

Study details: Findings are from the Canadian Healthy Infant Longitudinal Development (CHILD) Cohort Study, comprising a longitudinal birth cohort of 3,272 parents and infants recruited during pregnancy and followed from birth onwards.

Disclosures: This study was funded by the Canadian Institutes of Health Research and Allergy, Genes, and Environment Network of Centers of Excellence. The authors declared no conflicts of interest.

Source: Medeleanu M et al. J Allergy Clin Immunol. 2022 (Jan 16). Doi: 10.1016/j.jacig.2021.12.005

Key clinical point: Infections in early life increase the risk of developing atopic dermatitis (AD) later in infancy and early childhood.

Major finding: Prior to AD diagnosis, all infections including skin infection up to 2 years of age were more frequent in patients who subsequently developed AD vs. healthy controls (P < .001), with a significant association observed between having any infection before AD diagnosis and subsequent development of AD (adjusted odds ratio, 1.40; P < .001), which persisted up to 2 years of age.

Study details: Findings are from a population-based, nationwide case-control study including 5,454 patients (mean age 2.6±2.9 years) with AD matched with 16,362 healthy controls without AD.

Disclosures: This study is supported by the Ministry of Science and Technology and Taichung Veterans General Hospital. The authors declared no conflicts of interest.

Source: Lin T-L et al. J Eur Acad Dermatol Venereol. 2022 (Jan 9). Doi: 10.1111/jdv.17908

Key clinical point: Infections in early life increase the risk of developing atopic dermatitis (AD) later in infancy and early childhood.

Major finding: Prior to AD diagnosis, all infections including skin infection up to 2 years of age were more frequent in patients who subsequently developed AD vs. healthy controls (P < .001), with a significant association observed between having any infection before AD diagnosis and subsequent development of AD (adjusted odds ratio, 1.40; P < .001), which persisted up to 2 years of age.

Study details: Findings are from a population-based, nationwide case-control study including 5,454 patients (mean age 2.6±2.9 years) with AD matched with 16,362 healthy controls without AD.

Disclosures: This study is supported by the Ministry of Science and Technology and Taichung Veterans General Hospital. The authors declared no conflicts of interest.

Source: Lin T-L et al. J Eur Acad Dermatol Venereol. 2022 (Jan 9). Doi: 10.1111/jdv.17908

Key clinical point: Infections in early life increase the risk of developing atopic dermatitis (AD) later in infancy and early childhood.

Major finding: Prior to AD diagnosis, all infections including skin infection up to 2 years of age were more frequent in patients who subsequently developed AD vs. healthy controls (P < .001), with a significant association observed between having any infection before AD diagnosis and subsequent development of AD (adjusted odds ratio, 1.40; P < .001), which persisted up to 2 years of age.

Study details: Findings are from a population-based, nationwide case-control study including 5,454 patients (mean age 2.6±2.9 years) with AD matched with 16,362 healthy controls without AD.

Disclosures: This study is supported by the Ministry of Science and Technology and Taichung Veterans General Hospital. The authors declared no conflicts of interest.

Source: Lin T-L et al. J Eur Acad Dermatol Venereol. 2022 (Jan 9). Doi: 10.1111/jdv.17908